Stock BVX BIVICTRIX THERAPEUTICS PLC
Add to a list
To use this feature you must be a member
Log inSign up

Highlights BiVictriX Therapeutics plc

Equities

BVX

GB00BNXH3K91

Market Closed - London S.E.
Other stock markets
 11:35:06 2024-07-03 EDT 		5-day change 1st Jan Change
12.5 GBX 0.00% Intraday chart for BiVictriX Therapeutics plc 0.00% +19.05%
06-21 BiVictriX Therapeutics Plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
06-13 EARNINGS AND TRADING: Dialight trades in line; Petards swings to loss AN

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BiVictriX Therapeutics Plc Reports Earnings Results for the Full Year Ended December 31, 2023
CI
EARNINGS AND TRADING: Dialight trades in line; Petards swings to loss
AN
BiVictriX Therapeutics' Leukemia Treatment Shows Favorable Safety Profile
MT
BiVictriX Therapeutics Plc Announces Compelling Safety Profile of BVX001 in Pre-Clinical Models Supports Progression to Clinic
CI
BiVictriX Wins Development Grant for Ovarian Cancer Drug Conjugate
MT
EARNINGS AND TRADING: CT UK High Income tops benchmark, ups dividend
AN
BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment
MT
Bivictrix selects final sequences for lead tumour programme
AN
BiVictriX Therapeutics plc Announces Pipeline Update on Lead Solid Tumour Programme, Bvx002
CI
BiVictriX patent boost; 4Global deal extended
AN
BiVictriX Obtains Japanese Patent for Acute Myeloid Leukemia Drug Conjugate
MT
Bivictrix says BVX001 increases survival rates by more than double
AN
BiVictriX Therapeutics Plc Announces Chief Financial Officer Changes
CI
BiVictriX Therapeutics Plc Appoints Adrian Howd as Chief Business Officer
CI
AEW UK REIT appoints new chair; Oberon raises money
AN
Earnings Flash (BVX.L) BIVICTRIX THERAPEUTICS Posts H1 Loss GBX-1.77
MT
BiVictriX Therapeutics Plc Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Bivictrix Therapeutics granted US patent for cancer drug BVX001
AN
BiVictriX Therapeutics Secures US Patent for Lead Asset
MT
EARNINGS UPDATES: Ironveld sees interim pretax loss widen on costs
AN
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BVX Stock
  4. News BiVictriX Therapeutics plc
  5. Highlights